Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-6.9%
1 month
-32.5%
YTD
-18.18%
1 year
8%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
19 December 24 |
Shareholder Update
×
Shareholder Update |
17 December 24 |
Notification of cessation of securities - IRX
×
Notification of cessation of securities - IRX |
17 December 24 |
Application for quotation of securities - IRX
×
Application for quotation of securities - IRX |
17 December 24 |
Change of Director's Interest Notice - Sean Williams
×
Change of Director's Interest Notice - Sean Williams |
17 December 24 |
Change of Director's Interest Notice - James Barrie
×
Change of Director's Interest Notice - James Barrie |
17 December 24 |
Cleansing Notice
×
Cleansing Notice |
16 December 24 |
Issue of Securities Following General Meeting Approval
×
Issue of Securities Following General Meeting Approval |
16 December 24 |
Notification regarding unquoted securities - IRX
×
Notification regarding unquoted securities - IRX |
16 December 24 |
Proposed issue of securities - IRX
×
Proposed issue of securities - IRX |
29 November 24 |
Results of General Meeting
×
Results of General Meeting |
28 November 24 |
Director Appointment and Resignation
×
Director Appointment and Resignation |
28 November 24 |
Nov24 EGM Slides
×
Nov24 EGM Slides |
15 November 24 |
Ethics Approval for Phase 2 Clinical Trial of IRX-211
×
Ethics Approval for Phase 2 Clinical Trial of IRX-211 |
14 November 24 |
Change in substantial holding - Cannvalate
×
Change in substantial holding - Cannvalate |
31 October 24 |
Sep24 Quarterly Activities Report
×
Sep24 Quarterly Activities Report |
31 October 24 |
Sep24 Appendix 4C Cash Flow Report
×
Sep24 Appendix 4C Cash Flow Report |
29 October 24 |
General Meeting - Sample Proxy
×
General Meeting - Sample Proxy |
29 October 24 |
Notice of General Meeting
×
Notice of General Meeting |
29 October 24 |
General Meeting - Access Letter
×
General Meeting - Access Letter |
28 October 24 |
Change in substantial holding
×
Change in substantial holding |
24 October 24 |
Application for quotation of securities - IRX
×
Application for quotation of securities - IRX |
23 October 24 |
Proposed issue of securities - IRX
×
Proposed issue of securities - IRX |
23 October 24 |
Issue of Loan Conversion shares
×
Issue of Loan Conversion shares |
23 October 24 |
Cleansing Notice
×
Cleansing Notice |
18 October 24 |
$38.5m Funding to Fully Fund Clinical Development Plans
×
$38.5m Funding to Fully Fund Clinical Development Plans |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.